 | In a letter to the Institute for Clinical and Economic Review (ICER), the Partnership to Improve Patient Care (PIPC) submitted feedback on ICER's assessment of treatments for amyotrophic lateral sclerosis (ALS). |
The letter is critical of ICER's model structure for failing to appropriately represent a progressive disease such as ALS. PIPC also encourages ICER to factor in caregiver burden, as well as abandon the use of the discriminatory quality-adjusted life years (QALY) metric.
"Given the severity of the disease, it is imperative that patients are able to access treatments as they become available," wrote PIPC Chair Tony Coelho. "PIPC encourages ICER to revisit its modeling choices to ensure that the model accurately represents the needs of and treatment value to the ALS patient population."
"Given the severity of the disease, it is imperative that patients are able to access treatments as they become available," wrote PIPC Chair Tony Coelho. "PIPC encourages ICER to revisit its modeling choices to ensure that the model accurately represents the needs of and treatment value to the ALS patient population."
| icer_als_final_for_submission.pdf |
